TherVacB

New Concept to Fight Chronic Hepatitis B

TherVacB

New Hope for Hepatitis B Patients

TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B

European Commission and TherVacB join forces

The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.

A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.

 

The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.

b3lineicon|b3icon-lifebuoy||Lifebuoy

About TherVacB

b3lineicon|b3icon-user-arrows||User Arrows

For Patients

et|icon_group|

TherVacB Team

Inken Schmütz_400x400

“I am highly pleased that for the clinical trials of TherVacB we are able to cooperate with a consortium of Europe’s leading virologists, immunologists and hepatologis. This will be of great benefit for the patients chronically infected with the hepatitis B virus."

Ulrike Protzer
Project Coordinator
Helmholtz Zentrum München

Partners

European countries

Project duration (months)

Happy World Hepatitis Day 2022!

Happy World Hepatitis Day 2022!

Globally, 325 million people live with hepatitis, one of the most neglected diseases. On World Hepatitis Day 2022, the TherVacB project coordinator, Prof. Ulrike Protzer, joins the collective voices from across the world to raise awareness about Hepatitis B (HBV) and...

European Testing Week, 22-29 November 2021

European Testing Week, 22-29 November 2021

Get your one-off screening for hepatitis B from your GP in Germany Hepatitis B can be treated well at an early stage, hepatitis C can even be cured. In Germany, like in other countries and regions of the world, many people affected are unaware of their infection....

Animation movie

Enjoy our animation movie to understand the mission and approach of the TherVacB project!

TherVacB Publications

Find here scientific publications and technical articles from TherVacB project partners.

Read more about chronic hepatitis B, the virus, screening and testing for hepatitis C and B, therapeutic vaccination, and cure research.

All you need to know to understand Hepatitis B cure research – The HBV Cure FAQs

Watch the growing collection of short videos answering key questions on cure research raised by people living with Hepatitis B (HBV). The collection is a product of an international consortium of organizations, expert institutions and research projects working in and around Hepatitis B. Actively involved are ICE-HBV, Hepatitis B Foundation, World Hepatitis Alliance, HepBCommunity.org, Australian Centre for Hepatitis Virology, IP-cure-B, the Canadian HBV Network and TherVacB.

Load More...
TherVacB